A challenging drug development process in the era of personalized medicine
After years of hesitation a larger number of pharmaceutical and biotech companies are now supporting the idea of a more individualized pharmacotherapy. The companies that are now involved in this research-demanding area will have to face several challenges. The key factor for success will be an in-d...
Gespeichert in:
| Veröffentlicht in: | Drug discovery today 2011-10, Vol.16 (19), p.891-897 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 897 |
|---|---|
| container_issue | 19 |
| container_start_page | 891 |
| container_title | Drug discovery today |
| container_volume | 16 |
| creator | Jørgensen, Jan Trøst |
| description | After years of hesitation a larger number of pharmaceutical and biotech companies are now supporting the idea of a more individualized pharmacotherapy. The companies that are now involved in this research-demanding area will have to face several challenges. The key factor for success will be an in-depth molecular understanding of the pathophysiology and the mechanism of the drug under development. The one-disease-one-drug-one-target paradigm that has been prevailing for decades is history. Most diseases are heterogeneous and based on molecular profiling they can be divided into biological subgroups that each requires a specific pharmacological intervention. |
| doi_str_mv | 10.1016/j.drudis.2011.09.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_897814630</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S135964461100300X</els_id><sourcerecordid>897814630</sourcerecordid><originalsourceid>FETCH-LOGICAL-c361t-37e56045b958b7860616942e01efcdc2ccb431656838fd2aba6483226294071a3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqXwBwh5xyrBdhzH3iBVFU9VYgNry3Emrau8sNNK8PW4amHJZmYWd2buPQhdU5JSQsXdJq38tnIhZYTSlKiUUHKCplQWMsllxk7jnOUqEZyLCboIYUMIZSoX52jCqOK5FGSKXufYrk3TQLdy3QrHk7HADpp-aKEb8eB7CyFg1-FxDRi8wX2NB_Ch70zjvqHCLVTOug4u0VltmgBXxz5DH48P74vnZPn29LKYLxObCTomWQG5IDwvVS7LIpoQVCjOgFCobWWZtSXPqMiFzGRdMVMawWMcJpjipKAmm6Hbw93o7XMLYdStCxaaxnTQb4OWqpCUi4xEJT8ore9D8FDrwbvW-C9Nid5D1Bt9gKj3EDVROkKMazfHB9syhvtb-qUWBfcHAcSYOwdeB-ugsxGEBzvqqnf_f_gBR4mD0w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>897814630</pqid></control><display><type>article</type><title>A challenging drug development process in the era of personalized medicine</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Jørgensen, Jan Trøst</creator><creatorcontrib>Jørgensen, Jan Trøst</creatorcontrib><description>After years of hesitation a larger number of pharmaceutical and biotech companies are now supporting the idea of a more individualized pharmacotherapy. The companies that are now involved in this research-demanding area will have to face several challenges. The key factor for success will be an in-depth molecular understanding of the pathophysiology and the mechanism of the drug under development. The one-disease-one-drug-one-target paradigm that has been prevailing for decades is history. Most diseases are heterogeneous and based on molecular profiling they can be divided into biological subgroups that each requires a specific pharmacological intervention.</description><identifier>ISSN: 1359-6446</identifier><identifier>EISSN: 1878-5832</identifier><identifier>DOI: 10.1016/j.drudis.2011.09.010</identifier><identifier>PMID: 21945860</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Biomarkers ; Disease - etiology ; Disease - genetics ; Drug Discovery - methods ; Humans ; Models, Biological ; Molecular Diagnostic Techniques ; Pharmaceutical Preparations - administration & dosage ; Pharmaceutical Preparations - metabolism ; Precision Medicine - methods ; Systems Biology</subject><ispartof>Drug discovery today, 2011-10, Vol.16 (19), p.891-897</ispartof><rights>2011 Elsevier Ltd</rights><rights>Copyright © 2011 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c361t-37e56045b958b7860616942e01efcdc2ccb431656838fd2aba6483226294071a3</citedby><cites>FETCH-LOGICAL-c361t-37e56045b958b7860616942e01efcdc2ccb431656838fd2aba6483226294071a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S135964461100300X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21945860$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jørgensen, Jan Trøst</creatorcontrib><title>A challenging drug development process in the era of personalized medicine</title><title>Drug discovery today</title><addtitle>Drug Discov Today</addtitle><description>After years of hesitation a larger number of pharmaceutical and biotech companies are now supporting the idea of a more individualized pharmacotherapy. The companies that are now involved in this research-demanding area will have to face several challenges. The key factor for success will be an in-depth molecular understanding of the pathophysiology and the mechanism of the drug under development. The one-disease-one-drug-one-target paradigm that has been prevailing for decades is history. Most diseases are heterogeneous and based on molecular profiling they can be divided into biological subgroups that each requires a specific pharmacological intervention.</description><subject>Biomarkers</subject><subject>Disease - etiology</subject><subject>Disease - genetics</subject><subject>Drug Discovery - methods</subject><subject>Humans</subject><subject>Models, Biological</subject><subject>Molecular Diagnostic Techniques</subject><subject>Pharmaceutical Preparations - administration & dosage</subject><subject>Pharmaceutical Preparations - metabolism</subject><subject>Precision Medicine - methods</subject><subject>Systems Biology</subject><issn>1359-6446</issn><issn>1878-5832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EoqXwBwh5xyrBdhzH3iBVFU9VYgNry3Emrau8sNNK8PW4amHJZmYWd2buPQhdU5JSQsXdJq38tnIhZYTSlKiUUHKCplQWMsllxk7jnOUqEZyLCboIYUMIZSoX52jCqOK5FGSKXufYrk3TQLdy3QrHk7HADpp-aKEb8eB7CyFg1-FxDRi8wX2NB_Ch70zjvqHCLVTOug4u0VltmgBXxz5DH48P74vnZPn29LKYLxObCTomWQG5IDwvVS7LIpoQVCjOgFCobWWZtSXPqMiFzGRdMVMawWMcJpjipKAmm6Hbw93o7XMLYdStCxaaxnTQb4OWqpCUi4xEJT8ore9D8FDrwbvW-C9Nid5D1Bt9gKj3EDVROkKMazfHB9syhvtb-qUWBfcHAcSYOwdeB-ugsxGEBzvqqnf_f_gBR4mD0w</recordid><startdate>20111001</startdate><enddate>20111001</enddate><creator>Jørgensen, Jan Trøst</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20111001</creationdate><title>A challenging drug development process in the era of personalized medicine</title><author>Jørgensen, Jan Trøst</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c361t-37e56045b958b7860616942e01efcdc2ccb431656838fd2aba6483226294071a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Biomarkers</topic><topic>Disease - etiology</topic><topic>Disease - genetics</topic><topic>Drug Discovery - methods</topic><topic>Humans</topic><topic>Models, Biological</topic><topic>Molecular Diagnostic Techniques</topic><topic>Pharmaceutical Preparations - administration & dosage</topic><topic>Pharmaceutical Preparations - metabolism</topic><topic>Precision Medicine - methods</topic><topic>Systems Biology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jørgensen, Jan Trøst</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drug discovery today</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jørgensen, Jan Trøst</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A challenging drug development process in the era of personalized medicine</atitle><jtitle>Drug discovery today</jtitle><addtitle>Drug Discov Today</addtitle><date>2011-10-01</date><risdate>2011</risdate><volume>16</volume><issue>19</issue><spage>891</spage><epage>897</epage><pages>891-897</pages><issn>1359-6446</issn><eissn>1878-5832</eissn><abstract>After years of hesitation a larger number of pharmaceutical and biotech companies are now supporting the idea of a more individualized pharmacotherapy. The companies that are now involved in this research-demanding area will have to face several challenges. The key factor for success will be an in-depth molecular understanding of the pathophysiology and the mechanism of the drug under development. The one-disease-one-drug-one-target paradigm that has been prevailing for decades is history. Most diseases are heterogeneous and based on molecular profiling they can be divided into biological subgroups that each requires a specific pharmacological intervention.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>21945860</pmid><doi>10.1016/j.drudis.2011.09.010</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-6446 |
| ispartof | Drug discovery today, 2011-10, Vol.16 (19), p.891-897 |
| issn | 1359-6446 1878-5832 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_897814630 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Biomarkers Disease - etiology Disease - genetics Drug Discovery - methods Humans Models, Biological Molecular Diagnostic Techniques Pharmaceutical Preparations - administration & dosage Pharmaceutical Preparations - metabolism Precision Medicine - methods Systems Biology |
| title | A challenging drug development process in the era of personalized medicine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T02%3A58%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20challenging%20drug%20development%20process%20in%20the%20era%20of%20personalized%20medicine&rft.jtitle=Drug%20discovery%20today&rft.au=J%C3%B8rgensen,%20Jan%20Tr%C3%B8st&rft.date=2011-10-01&rft.volume=16&rft.issue=19&rft.spage=891&rft.epage=897&rft.pages=891-897&rft.issn=1359-6446&rft.eissn=1878-5832&rft_id=info:doi/10.1016/j.drudis.2011.09.010&rft_dat=%3Cproquest_cross%3E897814630%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=897814630&rft_id=info:pmid/21945860&rft_els_id=S135964461100300X&rfr_iscdi=true |